NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis $5.05 +0.02 (+0.40%) (As of 03:16 PM ET) Add Compare Share Share Today's Range$4.87▼$5.1150-Day Range$4.26▼$6.0052-Week Range$3.80▼$7.91Volume416,963 shsAverage Volume632,604 shsMarket Capitalization$610.48 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Exscientia alerts: Email Address Exscientia MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside38.6% Upside$7.00 Price TargetShort InterestHealthy2.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.25) to ($1.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.06 out of 5 starsMedical Sector487th out of 927 stocksBiological Products, Except Diagnostic Industry80th out of 154 stocks 3.0 Analyst's Opinion Consensus RatingExscientia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageExscientia has only been the subject of 2 research reports in the past 90 days.Read more about Exscientia's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.96% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Exscientia has recently decreased by 14.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EXAI. Previous Next 2.1 News and Social Media Coverage News SentimentExscientia has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Exscientia this week, compared to 5 articles on an average week.Search Interest10 people have searched for EXAI on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is a decrease of -5% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exscientia's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exscientia are expected to grow in the coming year, from ($1.25) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exscientia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during This 8-Day Profit Window? And when I say almost always… I really mean it. For over a year now, traders have had the chance to cash in during this time with an 83% success rate using these New Bitcoin Options. Now of course I can’t promise future returns or against losses…It’s coming up quick. About Exscientia Stock (NASDAQ:EXAI)Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More EXAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAI Stock News HeadlinesSeptember 11, 2024 | seekingalpha.comRecursion: AI Is Only As Good As The DataAugust 31, 2024 | msn.comExscientia Plc (EXAI): A Penny Stock That Will Make You a MillionaireSeptember 16, 2024 | DTI (Ad)Massive shakeup in defense contractingThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 29, 2024 | finance.yahoo.comExscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 16, 2024 | finance.yahoo.comNews Flash: 4 Analysts Think Exscientia plc (NASDAQ:EXAI) Earnings Are Under ThreatAugust 16, 2024 | markets.businessinsider.comMaintaining Hold Rating on Exscientia Plc Amid Anticipated Developments and Clinical MilestonesAugust 15, 2024 | theglobeandmail.comHow A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market UpdatesAugust 15, 2024 | finance.yahoo.comExscientia Business Update for Second Quarter and First Half 2024September 16, 2024 | DTI (Ad)Massive shakeup in defense contractingThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 14, 2024 | msn.comBarclays Downgrades Exscientia plc - Depositary Receipt () (EXAI)August 9, 2024 | msn.comTD Cowen Downgrades Exscientia plc - Depositary Receipt () (EXAI)August 9, 2024 | uk.finance.yahoo.comConsumer exhibiting 'selectivity' while spending on travelAugust 9, 2024 | sg.finance.yahoo.com(078100.TW)August 9, 2024 | finance.yahoo.comRecursion and Exscientia merge to form drug discovery companyAugust 8, 2024 | seekingalpha.comRecursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not OthersJuly 31, 2024 | msn.comWhy Do Hedge Funds Think That Exscientia plc (EXAI) Will Skyrocket?July 30, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Hold Rating on Exscientia Plc (EXAI)July 8, 2024 | investorplace.com3 Small-Cap Stocks With Explosive 2X Growth PotentialSee More Headlines Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2024Today9/16/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees280Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+41.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,560,000.00 Net Margins-620.99% Pretax Margin-656.65% Return on Equity-37.56% Return on Assets-26.19% Debt Debt-to-Equity Ratio0.06 Current Ratio5.93 Quick Ratio5.93 Sales & Book Value Annual Sales$21.02 million Price / Sales28.47 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.35Miscellaneous Outstanding Shares120,887,000Free Float101,062,000Market Cap$598.39 million OptionableOptionable Beta0.86 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. David Hallett Ph.D. (Age 55)Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director Mr. Ben R. Taylor (Age 47)CFO, Chief Strategy Officer & Executive Director Comp: $534.97kDr. Michael Krams M.D. (Age 63)Chief Medical Officer Ms. Eileen Jennings-BrownChief Information OfficerMs. Sara ShermanVice President of Investor RelationsMr. Dan IrelandExecutive VP of Legal & Company SecretaryMr. Parker MossExecutive Vice President of Corporate DevelopmentMs. Caroline RowlandChief People OfficerMr. Richard LawChief Business OfficerDr. John P. Overington Ph.D.Chief Data OfficerMore ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLRelay TherapeuticsNASDAQ:RLAYSchrödingerNASDAQ:SDGRImmunityBioNASDAQ:IBRXVerona PharmaNASDAQ:VRNAView All CompetitorsInstitutional OwnershipNovo Holdings A SBought 13,086,600 shares on 8/20/2024Ownership: 10.825%Susquehanna Fundamental Investments LLCBought 50,154 shares on 8/15/2024Ownership: 0.041%Susquehanna Portfolio Strategies LLCSold 16,533 shares on 8/15/2024Ownership: 0.014%Vanguard Personalized Indexing Management LLCBought 10,629 shares on 8/12/2024Ownership: 0.009%Federated Hermes Inc.Bought 22,500 shares on 8/8/2024Ownership: 0.019%View All Institutional Transactions EXAI Stock Analysis - Frequently Asked Questions How have EXAI shares performed this year? Exscientia's stock was trading at $6.41 at the start of the year. Since then, EXAI stock has decreased by 21.2% and is now trading at $5.05. View the best growth stocks for 2024 here. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) released its quarterly earnings data on Thursday, August, 15th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05. The company earned $5.60 million during the quarter. Exscientia had a negative trailing twelve-month return on equity of 37.56% and a negative net margin of 620.99%. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an initial public offering (IPO) on Friday, October 1st 2021. The company issued 13,850,000 shares at $20.00-$22.00 per share. Who are Exscientia's major shareholders? Top institutional shareholders of Exscientia include Novo Holdings A S (10.83%), Baillie Gifford & Co. (3.64%), Bank of New York Mellon Corp (0.32%) and Susquehanna Fundamental Investments LLC (0.04%). How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EXAI) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
